Consolidated Statements of Operations - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Revenue
Operating expenses:
General and administrative (including stock-based compensation (Note 7))	1,724,677	2,335,499
Depreciation	1,314	1,744
Research and development (including stock-based compensation (Note 7))	520,084	1,185,317
Total operating expenses	2,246,075	3,522,560
Loss from operations	(2,246,075)	(3,522,560)
Other expense (income):
Gain on extinguishment of liabilities		(875,852)
Conversion inducement		10,784
Interest expense	413,057	360,492
Total other expense (income)	413,057	(504,576)
Net loss	(2,659,132)	(3,017,984)
Net loss attributable to the noncontrolling interest	4,930	2,994
Net loss applicable to Bion's common stockholders	$ (2,654,202)	$ (3,014,990)
Net loss applicable to Bion's common stockholders per basic and diluted common share (in dollars per share)	$ (0.10)	$ (0.12)
Weighted-average number of common shares outstanding:
Basic and diluted (in shares)	26,522,326	24,439,059